Review of Promising Off-Label Use of Deucravacitinib

    September 2025 in “ International Journal of Molecular Sciences ”
    Yoshihito Mima, Masako Yamamoto, Ken Iozumi
    Studysummary This review reports on the potential for deucravacitinib, an oral TYK2 inhibitor approved for psoriasis, to treat various immune-mediated diseases, with emerging research suggesting possible uses in neurodegenerative diseases and certain cancers.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on mdpi.com →
    Discuss this study in the Community →

    Research cited in this study 11

    1. Treatment of Discoid Lupus Erythematosus Scarring Alopecia with Deucravacitinib: A Case Report SAGE Open Medical Case Reports · 2025
    2. Discoid Lupus Erythematosus Successfully Treated With Deucravacitinib JAAD Case Reports · 2024
    3. Innovative Therapeutic Strategies in TYK2-Targeted Treatments: From Cancer to Autoimmune Disorders ACS Medicinal Chemistry Letters · 2024
    4. European Expert Consensus Statement on the Systemic Treatment of Alopecia Areata JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology · 2024
    5. Inheritance-Specific Dysregulation of Th1 and Th17-Associated Cytokines in Alopecia Areata Biomolecules · 2023
    6. Rapid Hair Regrowth in an Alopecia Universalis Patient With Deucravacitinib: A Case Report SAGE open medical case reports · 2023
    7. The Efficacy and Safety of JAK Inhibitors for Alopecia Areata: A Systematic Review and Meta-Analysis of Prospective Studies Frontiers in pharmacology · 2022
    8. Ritlecitinib And Brepocitinib Demonstrate Significant Improvement In Scalp Alopecia Areata Biomarkers ˆThe ‰journal of allergy and clinical immunology/Journal of allergy and clinical immunology/˜The œjournal of allergy and clinical immunology · 2021
    9. The JAK/STAT Signaling Pathway: From Bench to Clinic Signal Transduction and Targeted Therapy · 2021
    10. Alopecia Areata as a Model for T Cell-Dependent Autoimmune Diseases Experimental Dermatology · 2012
    11. Alopecia Areata: A Tissue-Specific Autoimmune Disease of the Hair Follicle Autoimmunity Reviews · 2005